Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00935090 · ClinicalTrials.gov registry record
3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
A clinical trial of Lymphoma and Leukemia, sponsored by Barbara Ann Karmanos Cancer Institute.
- Recruiting
- Registry status
- 1
- Study location
NCT00935090 is a study of Lymphoma and Leukemia that is actively recruiting participants, run by Barbara Ann Karmanos Cancer Institute. The trial reports 1 study location across 1 state.
The verdict
NCT00935090, a study of Lymphoma and Leukemia, is actively recruiting participants, sponsored by Barbara Ann Karmanos Cancer Institute.
- RECRUITING
- Registry status
- 1
- Study location
Study Summary
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-\[18F\] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.
Conditions Studied
Interventions
- DEVICE 3'-deoxy-3'-[18F]fluorothymidine
Study Locations (1)
Michigan
- Barbara Ann Karmanos Cancer Institute - Detroit
Trial Details
| Field | Value |
|---|---|
| Start Date | 2009-09 |
| Est. Completion | 2028-05 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00935090
The ClinicalTrials.gov registry entry for NCT00935090 describes a study currently listed as recruiting, categorized as an unspecified phase. An enrollment target was not published in the registry record, which is common for early-stage or observational entries. The listed sponsor is Barbara Ann Karmanos Cancer Institute, which has 139 total studies on file at ClinicalTrials.gov.
The record links to 9 conditions, with Lymphoma appearing as the primary indexed condition, and to 1 intervention - of which 3'-deoxy-3'-[18F]fluorothymidine is the first listed.
NCT00935090 reports 1 study location spanning 1 distinct geographic area - top geographies include Michigan.
Frequently Asked Questions
What is clinical trial NCT00935090 about?
NCT00935090 is a clinical study titled "3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer". RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-\[18F\] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment. PURPOSE: This phase I trial is studying FLT PET imaging in patient...
What is the current status of trial NCT00935090?
This trial is currently recruiting. The study started on 2009-09. Estimated completion is 2028-05.
What conditions does trial NCT00935090 study?
This clinical trial studies the following conditions: Lymphoma, Leukemia, Myelodysplastic Syndromes, Unspecified Adult Solid Tumor, Protocol Specific, Brain and Central Nervous System Tumors.
What interventions are being tested in trial NCT00935090?
The interventions under investigation include: 3'-deoxy-3'-[18F]fluorothymidine (DEVICE).
Who is sponsoring clinical trial NCT00935090?
This trial is sponsored by Barbara Ann Karmanos Cancer Institute, which has 139 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00935090 being conducted?
This trial has 1 study location across Michigan. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Lymphoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Study of a Communication Training Intervention for Large B-Cell Lymphoma Providers
RECRUITING · NA
-
Epcoritamab in Patients With Follicular Lymphoma Not Accomplishing a CR With Upfront Chemoimmunotherapy
RECRUITING · Phase 2
-
Collection of Blood From Patients With Cancer, Other Tumors, or Tumor Predisposition Syndromes for Genetic Analysis
RECRUITING
-
Exercise as an Immune Adjuvant for Allogeneic Cell Therapies
RECRUITING · Early Phase 1
-
A Phase 1/2, Open-label Study of Valemetostat in Combination With Rituximab and Lenalidomide in Relapsed or Refractory Follicular Lymphoma
RECRUITING · Phase 1
-
Ascertainment of Families for Genetic Studies of Familial Lymphoproliferative Disorders
RECRUITING
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.